Screener
Summit Therapeutics SMMT Total Operating Expenses
Total Operating Expenses at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Summit Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingExpenses.
The source filing: Summit Therapeutics’s 10-Q, filed April 30, 2026.
- Filed
- Apr 30, 2026, 5:00 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001599298-26-000039
| Line item | Three Months Ended March 31, 2026 | 2025 |
|---|---|---|
| Operating expenses: | ||
| Research and development (1) | $132,618 | $51,265 |
| General and administrative | 62,594 | 15,586 |
| Total operating expenses | 195,212 | 66,851 |
| Other income, net | 5,788 | 3,938 |
| Net loss | $(189,424) | $(62,913) |
| Net loss per share: | ||
| Basic and diluted | $(0.24) | $(0.09) |
Item 1. Financial Statements.
FAQ
- What is Summit Therapeutics's total operating expenses?
- Summit Therapeutics (SMMT) reported total operating expenses of $195.21M in Q1 2026.
- How has Summit Therapeutics's total operating expenses changed year-over-year?
- Summit Therapeutics's total operating expenses increased by 192.0% year-over-year, from $66.85M to $195.21M.
- What is the long-term trend for Summit Therapeutics's total operating expenses?
- Over 4 years (2021 to 2025), Summit Therapeutics's total operating expenses has grown at a 78.0% compound annual growth rate (CAGR), from $108.96M to $1.09B.
- What does total operating expenses mean?
- The sum of all operating costs including COGS, SG&A, R&D, D&A, and other operating charges. Revenue minus total operating expenses equals operating income.
Ask your AI about Summit Therapeutics's total operating expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude